The effect of squalene on cellular energy and inflammation in type 2 diabetes patients
DOI:
https://doi.org/10.31989/dsn.v1i12.1025Abstract
Background: Squalene is a 30-carbon ring hydrocarbon in the triterpene class. Squalene as a bioactive compound has been shown to have several health benefits specifically in the reduction of diabetic symptoms, including anti-inflammatory effects.
Objective: The purpose of the study was to examine effect of squalene on specific parameters regarding energy production and inflammation in those with type 2 diabetes mellitus. These parameters included ATP, NAD/NADH, CoQ10, NFκB, IκB-alpha, IκK-alpha, and IκK-beta.
Methods: 150 volunteers were selected for this study split into 5 groups. Group 1 contained 30 healthy participants and served as the control. The remaining 120 participants were split into 4 groups containing 30 volunteers each. All the participants in groups 2, 3, 4, and 5 have type 2 diabetes mellitus. Group 2 did not receive any squalene while group 3, group 4, and group 5 all received an oral supplementation of squalene at 200 mg/day, 400 mg/day and 600 mg/day respectively. Participants were prescribed to take the oral supplementation of squalene for a total of 84 days. Blood samples were taken on days 1, 14, 28, 56, and 84 in five time periods. For all participants ATP, NAD/NADH, CoQ10, NFκB, IκB-α, IκK-α and IκK-β levels of all groups were evaluated.
Results: Throughout the 84 days there was a statistically significant difference when comparing the healthy group and the diabetic groups in reducing ATP, NAD/NADH and CoQ10 (P < 0.05) and increasing NFκB, IκB-α, IκK-α and IκK-β (P < 0.05). When compared, participants in groups 3, 4, and 5 also showed a statistically significant in the changes of ATP, NFκB, IκB-α, IκK-α and IκK-β levels.
Conclusions: Squalene as a bioactive compound can play an important role in reducing inflammatory mediators and increases energy production.

Keywords: squalene, diabetes mellitus, ATP production, NAD/NADH, Reactive oxygen species (ROS), CoQ10, NFκB, IkB-α, IκK-α, IκK-β
Downloads
Published
Issue
Section
License
Originality & Rights Assurance
By submitting, authors confirm the manuscript is original, not under consideration elsewhere, and does not infringe third-party rights. Authors are responsible for obtaining permission to reuse any third-party material.
Copyright & License (CC BY 4.0)
Authors retain copyright and grant Dietary Supplements and Nutraceuticals the right of first publication under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license permits unrestricted use, distribution, adaptation, and reproduction in any medium, including commercial use, provided the original author(s) and source are credited, and any changes are indicated.
Author Sharing/Self-Archiving
Authors may post, share, and redistribute the published article (PDF/HTML) anywhere (institutional repositories, websites, academic networks), with acknowledgment of the original publication in this journal and the DOI.
Correspondence & Post-Publication Dialogue
Correspondence regarding articles published in Dietary Supplements and Nutraceuticals.